Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIBIT-MESO-1
2015-001995-23Phase 2Completed
- Sponsor
- Fondazione NIBIT
- Start
- Sep 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab and durvalumab in mesothelioma, pleural mesothelioma and peritoneal mesothelioma, sponsored by Fondazione NIBIT. Primary endpoint: Objective response rate. Started Sep 2021; status: completed.
02
Drugs
tremelimumabdurvalumab
03
Conditions
mesotheliomapleural mesotheliomaperitoneal mesothelioma
Beyond the preview
Go deeper on 2015-001995-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001995-23.